STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

United Therapeutics (UTHR) Notice: 1,800 Restricted Shares to Be Sold

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

UNITED THERAPEUTICS (UTHR) Form 144 summary: A holder intends to sell 1,800 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate aggregate market value of $747,767.70. The shares were acquired on 07/13/2024 as restricted stock from the issuer and were fully paid on that date. The filing lists an approximate total outstanding share count of 45,226,262 and an approximate sale date of 09/19/2025. No securities were reported sold by the same person in the past three months. The filer certifies they are unaware of undisclosed material adverse information about the issuer.

Positive

  • None.

Negative

  • None.

Insights

TL;DR Proposed sale is a limited number of restricted shares executed through a broker; impact appears routine.

The filing documents a planned disposition of 1,800 restricted common shares with an aggregate market value of $747,767.70, to be executed via Morgan Stanley Smith Barney on NASDAQ around 09/19/2025. The shares were originally granted by the issuer on 07/13/2024 and fully paid the same day. No other sales by this person are reported in the prior three months. From a trading-flow perspective, this is a single-holder notice required by Rule 144 and, by itself, does not provide information about company performance.

TL;DR This is a compliance filing documenting a planned sale of restricted stock; governance implications are procedural.

The notice confirms the securities were acquired as restricted stock from the issuer and that the seller represents no undisclosed material adverse information exists. The use of a broker and the absence of other recent sales suggest the filer is following Rule 144 procedures for public disposition. The filing does not disclose any changes in officer/director status, control transfers, or additional governance actions.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the UTHR Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 1,800 common shares via Morgan Stanley Smith Barney with an aggregate market value of $747,767.70, to be sold on 09/19/2025 on the NASDAQ.

When and how were the securities acquired according to the filing?

The securities were acquired on 07/13/2024 as restricted stock from the issuer and payment was completed on that date.

Does the filer report any securities sold in the past three months for UTHR?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Which broker and exchange are named in the Form 144 for UTHR?

The broker is Morgan Stanley Smith Barney LLC and the named exchange for the proposed sale is the NASDAQ.

What certification does the seller provide in the remarks section?

The seller represents by signing the notice that they do not know of any material adverse information regarding the issuer that has not been publicly disclosed.
United Therapeutics Corp.

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Latest SEC Filings

UTHR Stock Data

21.03B
42.14M
1.77%
99.51%
5.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SILVER SPRING